key: cord-0810535-c2n1rrx7
authors: Tinay, Ilker; Ozden, Ender; Suer, Evren; Bozkurt, Ozan; Izol, Volkan; Sahin, Bahadir; Turkeri, Levent
title: The Early Impact of COVID-19 Pandemic on Surgical Urologic Oncology Practice in Turkey: Multi-Institutional Experience from Different Geographic Areas
date: 2020-05-20
journal: Urology
DOI: 10.1016/j.urology.2020.05.016
sha: c90c36037e6304710ff76b7327c32fc73543ed6a
doc_id: 810535
cord_uid: c2n1rrx7

nan

The human spread of a novel beta-coronavirus, i.e. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan in December 2019 (1) . COVID-19 was then designated as the name of the disease resulting from this infection which is short for "Coronavirus Disease 2019" (1). COVID-19 has been declared as a pandemic by the World Health Organization (WHO) on March 11, 2020, which is also the date when the first confirmed case in Turkey has been announced by the Ministry of Health. As in other countries, number of cases increased over time in correlation with the increasing number of testing as well as spread of the virus and as of April 30, 2020 there were 120,204 confirmed cases in Turkey, which ranked as 7 th after Germany. On April 11, 2020 almost 4 weeks after the first case, Turkey reported highest number of new cases per day and since than numbers for daily new cases started to decrease (2). Unlike many other European countries, there was no nationwide lockdown in Turkey and only certain age groups (≤20 and ≥65 years of age) are exposed to lockdown measures.

Like in many countries worldwide, urological practice in Turkey has also been limited to emergency procedures and selected oncological surgeries in order to use available resources for COVID-19 treatments. General recommendations for daily practice in urological oncology has been published recently from different sources (3, 4), however a potential concern has been raised if these recommendations can be applicable to different populations from different geographical areas of the world, which can be affected by national resources, socio-cultural circumstances and restrictive administrative regulations. In this report, we wanted to investigate the early impact of 2 . Number of all surgical procedures has been decreased but the distribution of surgeries for urothelial carcinoma did not change significantly. We observed a trend for not performing partial nephrectomy for small renal masses and surgeries for kidney cancer were limited mostly to radical nephrectomies and partial nephrectomy for selected cT1b and ≥cT2 tumors. In prostate cancer, there was a major shift to perform radical prostatectomy for unfavorable intermediate and high-risk patients.

The use of minimally invasive surgery (MIS), namely laparoscopic or robotassisted, during COVID-19 has been discouraged due to safety issues regarding the transmission of virus (5) . In line with these recommendations, there is a significant decrease in MIS between 2019 and 2020 (55.9% vs. 28.9%, p=0.003 -Chi-square), where laparoscopic or robot-assisted radical nephrectomy decreased from 61.5% to 23.1%, partial nephrectomy from 54.5% to 20% and radical prostatectomy from 58.1% to 26.7%, respectively. American Society of Anesthesiologists (ASA) scores according to the cancers are shown in Figure 1 . There was an increase of patients with highest ASA scores and the median Charlson Comorbidity Index (CCI) scores are also increased from 2019 to 2020 [ Table 1 ]. Two third of the "non-deferrable" patients with the highest ASA scores in 2020 are referred from local hospitals. Since most of the local hospitals in Turkey are occupied with COVID-19 patients and had to cancel all surgeries during the study period, we believe these measures appear to be the reason for increased number of patients with higher comorbidities in our patient cohort of 2020. One limitation of our report is that we do not have the data on how many of patients were referred from local hospitals in 2019, so we cannot make a conclusion on these data. However, the increased rate of patients with higher comorbidities has not been translated to an increased rate of postoperative complication (Figure 2 ). We believe that decreased number of cases per day during COVID-19 cleared off the pressure to manage several cases within a limited time period and this might be one of the reasons for decreased early (14 days after the surgery) postoperative complications according to the Clavien-Dindo classification in our patient cohort.

Our real-life data of the early period during COVID-19 pandemic shows a significant impact on surgical urologic oncology practice compared to the same period in 2019. These data represent the major reference institutions in different geographical areas in Turkey, where non-deferrable cases were redirected by the local hospitals during the study period. Our data underlines the fact that, during catastrophic situations such as the current pandemic, oncological surgeries should be centralized in tertiary centers in order to continue to treat patients with comorbidities and to achieve optimal outcomes in terms of complications. 

Report of the WHO-China Joint Mission on coronavirus disease 2019

Considerations in the triage of urologic surgeries during the COVID-19 pandemic

Urology practice during COVID-19 pandemic

Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China and Italy